In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avillion LLP

http://avillionllp.com

Latest From Avillion LLP

Abingworth Offers Home For Big Pharma Pipeline Projects

The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.

Financing Clinical Trials

Abingworth Raises $465m To Back And Build New Biotechs

The ABV 8 fund will invest $15m to $30m per company across the range from start-ups to development-stage companies.

Financing StartUps and SMEs

Merck KGaA Finds The Right Home For Disease-Modifying OA Agent In Novartis

Novartis has added an anti-osteoarthritic Nanobody, M6495, to its growing pipeline of candidates for the condition, in a €450m agreement with Merck KGaA that sees the latter deliver on its plans to find new homes for its osteoarthritis pipeline.

Deals Orthopedics

Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery

Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.

Financing Artificial Intelligence
See All

Company Information

  • Other Names / Subsidiaries
    • Avillion Group
    • Bond Avillion 2 Development LP
UsernamePublicRestriction

Register